Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

Leukemia

Volumn 24, Issue 5, 2010, Pages 1043-1049

  Terpos, E ^a   Berenson, J ^b   Cook, R J ^c   Lipton, A ^d   Coleman, R E ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^c UNIVERSITY OF WATERLOO   (Canada)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Multiple myeloma; Risk factor; Skeletal related event; Survival; Zoledronic acid

Indexed keywords

ALBUMIN; AMINO TERMINAL TELOPEPTIDE; LACTATE DEHYDROGENASE; NARCOTIC ANALGESIC AGENT; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BODY WEIGHT; BONE ATROPHY; BONE METABOLISM; BONE PAIN; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RACE; RISK ASSESSMENT;

EID: 77952423759     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.62     Document Type: Article

References (22)

1. Coleman RE. Metastatic bone disease: clinical features, patho-physiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
2. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
3. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
4. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009; 94: 372-379.
5. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003; 120: 235-242.
6. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007; 7: 346-353.
7. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069.
8. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
9. Saad F, Chen Y, Hei Y. Fractures negatively impact survival in patients with multiple myeloma or bone metastases from solid tumors. Eur J Cancer Suppl 2005; 3: 364 (abstract 1265).
10. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110: 1860-1867.
11. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464-2472. (Pubitemid 46999218)
12. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphospho-nate zoledronic acid. J Clin Oncol 2005; 23: 4925-4935.
13. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3: 228-236.
14. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
15. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
16. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
17. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201.
18. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007; 12: 1035-1043.
19. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
20. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004; 89: 567-577.
21. Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A et al. Incorporation of the bone marker carboxy-terminal telopep-tide of type-1 collagen improves prognostic information of the international staging system in newly diagnosed symptomatic multiple myeloma. Leukemia 2008; 22: 1767-1772.
22. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH et al. Overall survival among patients with multiple myeloma (MM) treated with zoledronic acid (ZOL). Clin Lympho-ma Myeloma 2009; 9 (Suppl 1): S12-S13 (abstract A088).